Compounds > gemcitabine

Page last updated: 2024-08-24

gemcitabine and mk-1775

gemcitabine has been researched along with mk-1775 in 16 studies

Research

Studies (16)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	10 (62.50)	24.3611
2020's	6 (37.50)	2.80

Authors

Authors	Studies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ	1
Brooks, D; De Oliveira, E; Demuth, T; Hidalgo, M; Hirai, H; Maitra, A; Mizuarai, S; Ottenhof, N; Rajeshkumar, NV; Shumway, SD; Watters, J	1
Aarts, M; Ashworth, A; Garcia-Murillas, I; Gevensleben, H; Hurd, MS; Sharpe, R; Shumway, SD; Toniatti, C; Turner, NC	1
Altiok, S; Bui, MM; Foroutan, P; Gillies, RJ; Kreahling, JM; Letson, D; Martinez, G; Raghavan, M; Razabdouski, T; Reed, D	1
Altiok, S; Foroutan, P; Gillies, RJ; Grove, O; Kreahling, JM; Lloyd, MC; Martinez, GV; Morse, DL; Raghavan, M; Reed, D	1
Dobbelstein, M; Li, Y; Saini, P; Sriraman, A	1
Lawrence, TS; Maybaum, J; Morgan, MA; Parsels, JD; Parsels, LA; Tanska, DM	1
Al-Hawaray, M; Cho, CS; Cuneo, KC; Devasia, T; Lawrence, TS; Maybaum, J; Morgan, MA; Nathan, H; Parsels, JD; Parsels, LA; Sahai, V; Schipper, MJ; Zalupski, MM	1
Sidaway, P	1
Balakrishnan, I; Desisto, J; Eberhardt, CG; Foreman, NK; Green, A; Griesinger, A; Moreira, DC; Pierce, A; Prince, E; Subramanian, A; Venkataraman, S; Vibhakar, R	1
Blagden, SP; Nicum, S	1
Bowering, V; Bruce, JP; Cabanero, M; Chen, E; Cristea, MC; Dhani, NC; Ellard, SL; Fleming, GF; Garg, S; Jenkins, S; Jones, GN; Karakasis, K; Kunos, CA; Lheureux, S; Mantia-Smaldone, G; Olawaiye, AB; Oza, AM; Pugh, TJ; Rath, P; Rodriguez-Canales, J; Stockley, T; Tan, Q; Tracy, M; Udagani, S; Wahner Hendrickson, AE; Wang, L; Weberpals, JI; Welch, S	1
Killock, D	1
Bowering, V; Chang, K; Dhani, NC; Karakasis, K; Kavak, N; Lheureux, S; Madariaga, A; Mitchell, SA; Oza, AM; Pittman, T; Quintos, J; Ramsahai, J; Wang, L; Welch, SA	1
Chen, CP; Hsiao, YT; Huang, WK; Lo, CH; Pan, YR; Wu, CE; Yeh, CN	1

Trials

4 trial(s) available for gemcitabine and mk-1775

Article	Year
Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas. PloS one, 2013, Volume: 8, Issue:3 Topics: Adolescent; Adult; Animals; Antimetabolites, Antineoplastic; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line, Tumor; Child; Child, Preschool; Deoxycytidine; Drug Synergism; Female; Femoral Neoplasms; Gemcitabine; Humans; Male; Mice; Mice, SCID; Middle Aged; Neoplasm Transplantation; Nuclear Proteins; Osteosarcoma; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Transplantation, Heterologous; Xenograft Model Antitumor Assays	2013
Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 10-10, Volume: 37, Issue:29 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Chemoradiotherapy; Deoxycytidine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidinones; Survival Rate	2019
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet (London, England), 2021, 01-23, Volume: 397, Issue:10271 Topics: Antimetabolites, Antineoplastic; Canada; Deoxycytidine; Double-Blind Method; Enzyme Inhibitors; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Pyrazoles; Pyrimidinones; Survival; United States	2021
Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian ca Gynecologic oncology, 2022, Volume: 167, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Fatigue; Female; Gemcitabine; Humans; Ovarian Neoplasms; Platinum	2022

Other Studies

12 other study(ies) available for gemcitabine and mk-1775

Article	Year
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15 Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship	2013
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, May-01, Volume: 17, Issue:9 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; Disease Progression; Drug Synergism; Female; Gemcitabine; Genes, p53; Humans; Mice; Mice, Nude; Mutation; Neoplasms; Nuclear Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Tumor Burden; Xenograft Model Antitumor Assays	2011
Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer discovery, 2012, Volume: 2, Issue:6 Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Checkpoint Kinase 1; Cyclins; Deoxycytidine; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Mitosis; Nuclear Proteins; Polycomb Repressive Complex 2; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Quinolines; S Phase; Thiazoles; Thiophenes; Transcription Factors; Tumor Burden; Tumor Suppressor Protein p53; Urea; Xenograft Model Antitumor Assays	2012
Diffusion MRI and novel texture analysis in osteosarcoma xenotransplants predicts response to anti-checkpoint therapy. PloS one, 2013, Volume: 8, Issue:12 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Cycle Checkpoints; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Female; Gemcitabine; Humans; Mice; Mice, SCID; Middle Aged; Molecular Targeted Therapy; Osteosarcoma; Prognosis; Pyrazoles; Pyrimidines; Pyrimidinones; Treatment Outcome; Xenograft Model Antitumor Assays	2013
Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors. Oncotarget, 2015, Oct-20, Volume: 6, Issue:32 Topics: Caspases; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cell Survival; Deoxycytidine; Enzyme Activation; Flow Cytometry; Gemcitabine; HCT116 Cells; Histones; Humans; Imidazoles; Immunoblotting; Microscopy, Confocal; Mitosis; Mutation; Nuclear Proteins; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-mdm2; Pyrazoles; Pyrimidines; Pyrimidinones; Tumor Suppressor Protein p53	2015
The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors. Cell cycle (Georgetown, Tex.), 2018, Volume: 17, Issue:9 Topics: Analysis of Variance; Biomarkers, Tumor; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Replication; Gemcitabine; Histones; Humans; Nucleosides; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Roscovitine; Staining and Labeling	2018
WEE1 kinase inhibitor shows promise. Nature reviews. Clinical oncology, 2019, Volume: 16, Issue:10 Topics: Cell Cycle Proteins; Deoxycytidine; Gemcitabine; Humans; Nuclear Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones	2019
Targeting WEE1 in Pancreatic Cancer. Cancer discovery, 2019, Volume: 9, Issue:10 Topics: Adenocarcinoma; Cell Cycle Proteins; Deoxycytidine; Gemcitabine; Humans; Nuclear Proteins; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidinones	2019
Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine. Journal of neuro-oncology, 2020, Volume: 147, Issue:3 Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cerebellar Neoplasms; Deoxycytidine; Enzyme Inhibitors; Female; Gemcitabine; Genes, myc; Humans; Medulloblastoma; Mice, Transgenic; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidinones	2020
A source of hope for platinum-resistant ovarian cancer? Lancet (London, England), 2021, 01-23, Volume: 397, Issue:10271 Topics: Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Ovarian Neoplasms; Platinum; Pyrazoles; Pyrimidinones	2021
WEE1 inhibition after platinum resistance. Nature reviews. Clinical oncology, 2021, Volume: 18, Issue:4 Topics: Cell Cycle Proteins; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Ovarian Neoplasms; Platinum; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidinones	2021
Wee1 inhibition by MK1775 potentiates gemcitabine through accumulated replication stress leading to apoptosis in biliary tract cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 166 Topics: Animals; Apoptosis; Biliary Tract Neoplasms; Disease Models, Animal; Gemcitabine; Humans; Mice; Tumor Suppressor Protein p53	2023